We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Pacific Biosciences of California (PACB - Free Report) to post quarterly loss of -$0.18 per share in its upcoming report, which indicates a year-over-year increase of 10%. Revenues are expected to be $36.46 million, up 1.3% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Pacific Biosciences metrics that Wall Street analysts commonly model and monitor.
The consensus estimate for 'Revenue- Product- Instrument' stands at $10.90 million. The estimate points to a change of -25.9% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- Product' of $31.18 million. The estimate suggests a change of -1.8% year over year.
It is projected by analysts that the 'Revenue- Service and other' will reach $5.09 million. The estimate indicates a change of +19.3% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Product- Consumable' at $20.29 million. The estimate points to a change of +19.3% from the year-ago quarter.
Shares of Pacific Biosciences have demonstrated returns of -16.9% over the past month compared to the Zacks S&P 500 composite's +0.6% change. With a Zacks Rank #3 (Hold), PACB is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics
Wall Street analysts expect Pacific Biosciences of California (PACB - Free Report) to post quarterly loss of -$0.18 per share in its upcoming report, which indicates a year-over-year increase of 10%. Revenues are expected to be $36.46 million, up 1.3% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Pacific Biosciences metrics that Wall Street analysts commonly model and monitor.
The consensus estimate for 'Revenue- Product- Instrument' stands at $10.90 million. The estimate points to a change of -25.9% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- Product' of $31.18 million. The estimate suggests a change of -1.8% year over year.
It is projected by analysts that the 'Revenue- Service and other' will reach $5.09 million. The estimate indicates a change of +19.3% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Product- Consumable' at $20.29 million. The estimate points to a change of +19.3% from the year-ago quarter.
View all Key Company Metrics for Pacific Biosciences here>>>Shares of Pacific Biosciences have demonstrated returns of -16.9% over the past month compared to the Zacks S&P 500 composite's +0.6% change. With a Zacks Rank #3 (Hold), PACB is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .